Vaxart director receives stock and option awards
Vaxart, Inc. director David E. Wheadon received equity awards on July 16, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Vaxart, Inc. director David E. Wheadon received equity awards on July 16, 2026. He was granted 39,400 shares of common stock, bringing his direct holdings to 86,150 shares, plus stock options for 78,700 shares at an exercise price of $0.5149, expiring July 16, 2036. Both the stock award and options vest on the earlier of the date immediately prior to Vaxart’s 2027 annual meeting of stockholders and July 16, 2027, the first anniversary of the grant.
Insider Trade Summary
Grant/Award: 118,100 shares
Grant/Award
2 txns
Insider
Wheadon David E.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) F2 | 78,700 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 39,400 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (right to buy) — 78,700 contracts (Direct);
Common Stock — 86,150 shares (Direct)
Footnotes (2)
- F1. Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant.
- F2. The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant.
Key Figures
Common shares granted: 39,400 shares
Shares owned after grant: 86,150 shares
Options granted: 78,700 options
+3 more
6 metrics
Common shares granted
39,400 shares
Grant of common stock to David E. Wheadon on July 16, 2026
Shares owned after grant
86,150 shares
Direct Vaxart common stock holdings following the award
Options granted
78,700 options
Stock options (right to buy) granted on July 16, 2026
Option exercise price
$0.5149 per share
Exercise price for 78,700 stock options held by Wheadon
Option expiration
July 16, 2036
Expiration date of the stock options granted to Wheadon
Vesting latest date
July 16, 2027
Latest vesting date, or earlier date immediately prior to 2027 annual meeting
Key Terms
restricted stock units, Stock Options (right to buy), exercise price, expiration date, +1 more
5 terms
restricted stock units financial
"Grant of shares upon vesting of restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (right to buy) financial
"Security title listed as Stock Options (right to buy)."
exercise price financial
"conversion or exercise price reported as 0.5149 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"Options show an expiration date of 2036-07-16."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual meeting of stockholders financial
"Awards vest on the earlier of the date immediately prior to the 2027 annual meeting of stockholders."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Vaxart (VXRT) report for David E. Wheadon?
Vaxart reported that director David E. Wheadon received equity awards on July 16, 2026, including 39,400 shares of common stock and stock options covering 78,700 shares of common stock, both granted as compensation rather than through open-market purchases.
What stock options were granted to David E. Wheadon by Vaxart (VXRT)?
Wheadon received stock options for 78,700 shares of Vaxart common stock at an exercise price of $0.5149 per share. These options are reported as directly owned and have an expiration date of July 16, 2036, with vesting tied to 2027 milestones.
When do David E. Wheadon’s new Vaxart (VXRT) equity awards vest?
Both the stock grant and options vest on the earlier of the date immediately prior to Vaxart’s 2027 annual meeting of stockholders and July 16, 2027. The filing describes this as the first anniversary of the grant date for these 2026 awards.
What is the exercise price and expiration for Wheadon’s Vaxart (VXRT) options?
The options granted to Wheadon have an exercise price of $0.5149 per share and expire on July 16, 2036. They cover 78,700 underlying shares of common stock and follow the vesting schedule linked to the 2027 annual meeting or July 16, 2027.
Was the Vaxart (VXRT) insider award a market purchase or a compensation grant?
The transactions are reported with code A as a grant, award, or other acquisition, not market purchases. Both the 39,400-share common stock award and the 78,700-share option grant were issued at a reported price of $0.00 per share as compensation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates